DOCSLIB.ORG

Supplementary Table S5

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

Supplementary Table S5: Myofibroblastic signature associated to proteins up-regulated in whole cellular extract and conditioned medium of CAFs Accession Description Short name CAFs/NFs St dev CAFs/NFs Myofibroblast marker according to Experiment P02675 Fibrinogen beta chain FGB 23.71 1.49 HPA (Smooth muscle staining) WCE P35749 Myosin-11 MYH11 12.14 6.14 HPA (Smooth muscle staining) WCE P68032 Actin, alpha cardiac muscle 1 ACTC1 4.63 0.02 HPA (Smooth muscle staining) CM Q96HC4 PDZ and LIM domain protein 5 PDLIM5 4.15 0.02 BioGPS (Smooth muscle expression) WCE P62736 Actin, aortic smooth muscle ACTA2 4.15 0.53 HPA (Smooth muscle staining) WCE P24821 Tenascin TNC 3.45 0.08 HPA (Smooth muscle staining) CM P07996 Thrombospondin-1 THBS1 3.42 0.01 BioGPS (Smooth muscle expression) CM P51911 Calponin-1 CNN1 3.15 0.40 HPA (Smooth muscle staining) WCE Q16270 Insulin-like growth factor-binding protein 7 IGFBP7 3.12 0.10 BioGPS (Smooth muscle expression) CM Q9UMS6 Synaptopodin-2 SYNPO2 2.80 0.07 HPA (Smooth muscle staining) WCE P09493 Tropomyosin alpha-1 chain TPM1 2.64 0.05 BioGPS (Smooth muscle expression) WCE P21980 Protein-glutamine gamma-glutamyltransferase 2 TGM2 2.60 0.01 HPA (Smooth muscle staining) WCE Q6UVK1 Chondroitin sulfate proteoglycan 4 CSPG4 2.54 0.11 HPA (Smooth muscle staining) WCE P24844 Myosin regulatory light polypeptide 9 MYL9 2.41 0.19 HPA (Smooth muscle staining) WCE P07951 Tropomyosin beta chain TPM2 2.36 0.39 BioGPS (Smooth muscle expression) WCE P55290 Cadherin-13 CDH13 2.33 0.34 HPA (Smooth muscle staining) WCE Q9Y4K0 Lysyl oxidase homolog 2 LOXL2 2.27 0.19 BioGPS (Smooth muscle expression) CM Q01995 Transgelin TAGLN 2.26 0.09 BioGPS (Smooth muscle expression) WCE P08572 Collagen alpha-2(IV) chain COL4A2 2.14 0.15 HPA (Smooth muscle staining) CM Q05682 Caldesmon CALD1 2.12 0.02 BioGPS (Smooth muscle expression) WCE P02751 Fibronectin FN1 2.10 0.11 BioGPS (Smooth muscle expression) WCE Q15746 Myosin light chain kinase, smooth muscle MYLK 2.02 0.25 HPA (Smooth muscle staining) WCE P05121 Plasminogen activator inhibitor 1 SERPINE1 2.01 0.06 BioGPS (Smooth muscle expression) CM P21333 Filamin-A FLNA 1.98 0.11 BioGPS (Smooth muscle expression) CM P60660 Myosin light polypeptide 6 MYL6 1.90 0.04 BioGPS (Smooth muscle expression) WCE P13797 Plastin-3 PLS3 1.86 0.08 BioGPS (Smooth muscle expression) WCE P09486 SPARC SPARC 1.84 0.10 BioGPS (Smooth muscle expression) CM P05161 Interferon-induced 17 kDa protein ISG15 1.79 0.00 HPA (Smooth muscle staining) WCE Q99685 Monoglyceride lipase MGLL 1.79 0.05 HPA (Smooth muscle staining) WCE P08123 Collagen alpha-2(I) chain COL1A2 1.78 0.42 BioGPS (Smooth muscle expression) WCE Q15417 Calponin-3 CNN3 1.76 0.04 HPA (Smooth muscle staining) WCE P51636 Caveolin-2 CAV2 1.73 0.00 HPA (Smooth muscle staining) WCE Q13642 Four and a half LIM domains protein 1 FHL1 1.72 0.02 HPA (Smooth muscle staining) WCE P12814 Alpha-actinin-1 ACTN1 1.71 0.05 BioGPS (Smooth muscle expression) WCE P07355 Annexin A2 ANXA2 1.71 0.22 BioGPS (Smooth muscle expression) CM P23528 Cofilin-1 CFL1 1.68 0.09 BioGPS (Smooth muscle expression) CM Q14192 Four and a half LIM domains protein 2 FHL2 1.68 0.15 BioGPS (Smooth muscle expression) WCE Q9Y3X0 Coiled-coil domain-containing protein 9 CCDC9 1.67 0.02 HPA (Smooth muscle staining) WCE Q93052 Lipoma-preferred partner LPP 1.66 0.00 HPA (Smooth muscle staining) WCE P62158 Calmodulin CALM1 1.61 0.11 HPA (Smooth muscle staining) WCE O00469 Procollagen-lysine,2-oxoglutarate 5-dioxygenase 2 PLOD2 1.57 0.09 BioGPS (Smooth muscle expression) WCE Q12841 Follistatin-related protein 1 FSTL1 1.57 0.07 BioGPS (Smooth muscle expression) CM P02794 Ferritin heavy chain FTH1 1.56 0.07 BioGPS (Smooth muscle expression) WCE P08603 Complement factor H CFH 1.53 0.12 HPA (Smooth muscle staining) CM Q9UBR2 Cathepsin Z CTSZ 1.51 0.08 HPA (Smooth muscle staining) WCE O76061 Stanniocalcin-2 STC2 0.67 0.03 BioGPS (Smooth muscle expression) CM P02452 Collagen alpha-1(I) chain COL1A1 0.66 0.05 BioGPS (Smooth muscle expression) CM Q15582 Transforming growth factor-beta-induced protein ig-h3 TGFBI 0.65 0.05 BioGPS (Smooth muscle expression) CM Q99536 Synaptic vesicle membrane protein VAT-1 homolog VAT1 0.62 0.01 BioGPS (Smooth muscle expression) WCE Q8NBS9 Thioredoxin domain-containing protein 5 TXNDC5 0.62 0.07 BioGPS (Smooth muscle expression) CM Q13641 Trophoblast glycoprotein TPBG 0.62 0.04 BioGPS (Smooth muscle expression) WCE P35555 Fibrillin-1 FBN1 0.62 0.09 BioGPS (Smooth muscle expression) CM P07093 Glia-derived nexin SERPINE2 0.57 0.08 BioGPS (Smooth muscle expression) CM Q16363 Laminin subunit alpha-4 LAMA4 0.56 0.11 BioGPS (Smooth muscle expression) CM O00264 Membrane-associated progesterone receptor component 1 PGRMC1 0.56 0.06 HPA (Smooth muscle staining) WCE P55083 Microfibril-associated glycoprotein 4 MFAP4 0.44 0.06 HPA (Smooth muscle staining) CM P50454 Serpin H1 SERPINH1 0.44 0.03 BioGPS (Smooth muscle expression) CM O00391 Sulfhydryl oxidase 1 QSOX1 0.40 0.04 BioGPS (Smooth muscle expression) CM P24592 Insulin-like growth factor-binding protein 6 IGFBP6 0.40 0.05 BioGPS (Smooth muscle expression) CM P08253 72 kDa type IV collagenase MMP2 0.39 0.01 BioGPS (Smooth muscle expression) CM P01033 Metalloproteinase inhibitor 1 TIMP1 0.38 0.04 BioGPS (Smooth muscle expression) CM Q4LDE5 on Willebrand factor type A, EGF and pentraxin domain-containing p SVEP1 0.36 0.05 HPA (Smooth muscle staining) CM P03956 Interstitial collagenase MMP1 0.35 0.02 BioGPS (Smooth muscle expression) CM Q9BUD6 Spondin-2 SPON2 0.33 0.01 HPA (Smooth muscle staining) CM P07585 Decorin DCN 0.31 0.04 HPA (Smooth muscle staining) CM P05155 Plasma protease C1 inhibitor SERPING1 0.30 0.08 HPA (Smooth muscle staining) CM P36955 Pigment epithelium-derived factor SERPINF1 0.28 0.02 HPA (Smooth muscle staining) CM Q15063 Periostin POSTN 0.20 0.04 BioGPS (Smooth muscle expression) CM P02787 Serotransferrin TF 0.05 0.01 HPA (Smooth muscle staining) CM Supplementary Table S5: Markers CAFs expressed preferentially in tumoral stroma of colorectal cancer using inmunohistochemistry of Human Protein Atlas Accession Description Short name Experiment CAFs/NFs St dev CAFs/NFs HPA antibody Patient id HPA (Tumoral stroma) HPA (Tumoral epithelial) P62736 Actin, aortic smooth muscle ACTA2 WCE 2.07 0.53 HPA041271 4382 yes no P12814 Alpha-actinin-1 ACTN1 WCE 1.70 0.05 CAB004303 2060 yes no P07355 Annexin A2 ANXA2 CM 1.71 0.22 CAB004311 1898 yes yes P21810 Biglycan BGN CM 1.83 0.00 HPA003157 349 yes no P62158 Calmodulin CALM1 WCE 1.61 0.11 CAB018558 1898 yes yes P51636 Caveolin-2 CAV2 WCE 1.73 0.00 CAB013488 3264 yes no P55290 Cadherin-13 CDH13 WCE 2.33 0.34 CAB025863 2096 yes no P08603 Complement factor H CFH CM 1.53 0.11 CAB016385 3408 yes no P51911 Calponin-1 CNN1 WCE 3.15 0.40 CAB000007 237 yes no Q15417 Calponin-3 CNN3 WCE 1.75 0.04 CAB009849 2096 yes no P08572 Collagen alpha-2(IV) chain COL4A2 CM 2.14 0.16 CAB10751 2957 yes no Q6UVK1 Chondroitin sulfate proteoglycan 4 CSPG4 WCE 2.54 0.11 CAB016189 2948 yes yes Q9UBP4 Dickkopf-related protein 3 DKK3 CM 2.80 0.18 CAB024949 2948 yes no P02675 Fibrinogen beta chain FGB WCE 23.67 1.49 HPA001900 2002 yes no Q14192 Four and a half LIM domains protein 2 FHL2 WCE 1.67 0.15 HPA005922 2096 yes no P21333 Filamin-A FLNA CM 1.99 0.10 HPA001115 1454 yes no P02751 Fibronectin FN1 WCE 2.10 0.11 CAB00126 1957 yes no Q12841 Follistatin-related protein 1 FSTL1 CM 1.58 0.07 HPA035251 2948 yes no P02042 Hemoglobin subunit delta HBD WCE 1.77 0.12 CAB037087 2616 yes no Q16270 Insulin-like growth factor-binding protein 7 IGFBP7 CM 3.13 0.09 HPA002196 4089 yes no Q93052 Lipoma-preferred partner LPP WCE 1.66 0.00 HPA011133 2957 yes no Q99685 Monoglyceride lipase MGLL WCE 1.79 0.05 HPA011994 2957 yes no P35749 Myosin-11 MYH11 WCE 12.13 6.13 HPA015310 2001 yes no P35579 Myosin-9 MYH9 WCE 1.90 0.10 CAB015386 2948 yes no P24844 Myosin regulatory light polypeptide 9 MYL9 WCE 2.41 0.19 HPA039262 1960 yes no Q15746 Myosin light chain kinase, smooth muscle MYLK WCE 2.02 0.25 HPA031677 3782 yes no Q96HC4 PDZ and LIM domain protein 5 PDLIM5 WCE 4.15 0.02 CAB013511 3074 yes no O00469 Procollagen-lysine,2-oxoglutarate 5-dioxygenase 2 PLOD2 WCE 1.57 0.09 CAB025898 2096 yes no P13797 Plastin-3 PLS3 WCE 1.86 0.08 HPA020433 2616 yes no P05121 Plasminogen activator inhibitor 1 SERPINE1 CM 2.02 0.05 HPA050039 2616 yes no P09486 SPARC SPARC CM 1.85 0.09 CAB002306 1424 yes no Q9UMS6 Synaptopodin-2 SYNPO2 WCE 2.79 0.07 HPA030665 1898 yes no Q01995 Transgelin TAGLN WCE 2.26 0.09 HPA019467 2957 yes no P21980 Protein-glutamine gamma-glutamyltransferase 2 TGM2 WCE 2.59 0.01 HPA029518 2960 yes no P24821 Tenascin TNC CM 3.46 0.06 HPA004823 2002 yes no P09493 Tropomyosin alpha-1 chain TPM1 WCE 2.64 0.05 HPA009066 2001 yes no.
Recommended publications

  • Comparative Gene Expression Profiling of Stromal Cell Matrices

    ell Res C ea m rc te h S & f o T h l Journal of Tiwari et al., J Stem Cell Res Ther 2013, 3:4 e a r n a r p u DOI: 10.4172/2157-7633.1000152 y o J ISSN: 2157-7633 Stem Cell Research & Therapy Research Article Open Access Comparative Gene Expression Profiling of Stromal Cell Matrices that Support Expansion of Hematopoietic Stem/Progenitor Cells Abhilasha Tiwari1,2, Christophe Lefevre2, Mark A Kirkland2*, Kevin Nicholas2 and Gopal Pande1* 1CSIR-Centre for Cellular and Molecular Biology (CCMB), Hyderabad, India 2Deakin University, Waurn Ponds, Geelong, VIC, Australia Abstract The bone marrow microenvironment maintains a stable balance between self-renewal and differentiation of hematopoietic stem/progenitor cells (HSPCs). This microenvironment, also termed the “hematopoietic niche”, is primarily composed of stromal cells and their extracellular matrices (ECM) that jointly regulate HSPC functions. Previously, we have demonstrated that umbilical cord blood derived HSPCs can be maintained and expanded on stromal cell derived acellular matrices that mimic the complexity of the hematopoietic niche. The results indicated that matrices prepared at 20% O2 with osteogenic medium (OGM) were best suited for expanding committed HSPCs, whereas, matrices prepared at 5% O2 without OGM were better for primitive progenitors. Based upon these results we proposed that individual constituents of these matrices could be responsible for regulation of specific HSPC functions. To explore this hypothesis, we have performed comparative transcriptome profiling of these matrix producing cells, which identified differential expression of both known niche regulators, such as Wnt4, Angpt2, Vcam and Cxcl12, as well as genes not previously associated with HSPC regulation, such as Depp.
  • Supplemental Material Table of Contents

    Supplemental Material Table of Contents

    Supplemental material Table of Contents Detailed Materials and Methods ......................................................................................................... 2 Perioperative period ........................................................................................................................... 2 Ethical aspects ................................................................................................................................... 4 Evaluation of heart failure ................................................................................................................. 4 Sample preparation for ANP mRNA expression .................................................................................. 5 Sample preparation for validative qRT-PCR (Postn, Myh7, Gpx3, Tgm2) ............................................ 6 Tissue fibrosis .................................................................................................................................... 7 Ventricular remodeling and histological tissue preservation ................................................................ 8 Evaluation of the histological preservation of cardiac tissue ................................................................ 9 Sample preparation and quantitative label-free proteomics analyses .................................................. 10 Statistical methods ........................................................................................................................... 12 References ........................................................................................................................................
  • A Single-Cell Transcriptional Atlas Identifies Extensive Heterogeneity in the Cellular Composition of Tendons

    A Single-Cell Transcriptional Atlas Identifies Extensive Heterogeneity in the Cellular Composition of Tendons

    bioRxiv preprint doi: https://doi.org/10.1101/801266; this version posted October 10, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. A single-cell transcriptional atlas identifies extensive heterogeneity in the cellular composition of tendons Jacob B Swanson1, Andrea J De Micheli2, Nathaniel P Disser1, Leandro M Martinez1, Nicholas R Walker1,3, Benjamin D Cosgrove2, Christopher L Mendias1,3,* 1Hospital for Special Surgery, New York, NY, USA 2Meining School of Biomedical Engineering, Cornell University, Ithaca, NY, USA 3Department of Physiology and Biophysics, Weill Cornell Medical College, New York, NY, USA *Corresponding Author Christopher Mendias, PhD Hospital for Special Surgery 535 E 70th St New York, NY 10021 USA +1 212-606-1785 [email protected] Keywords: tenocyte; tendon fibroblast; pericyte; single-cell RNA sequencing bioRxiv preprint doi: https://doi.org/10.1101/801266; this version posted October 10, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Abstract Tendon is a dense, hypocellular connective tissue that transmits forces between muscles and bones. Cellular heterogeneity is increasingly recognized as an important factor in the biological basis of tissue homeostasis and disease, but little is known about the diversity of cells that populate tendon. Our objective was to explore the heterogeneity of cells in mouse Achilles tendons using single-cell RNA sequencing. We identified 13 unique cell types in tendons, including 4 previously undescribed populations of fibroblasts.
  • Dickkopf-1 Promotes Hematopoietic Regeneration Via Direct and Niche-Mediated Mechanisms

    Dickkopf-1 Promotes Hematopoietic Regeneration Via Direct and Niche-Mediated Mechanisms

    ARTICLES Dickkopf-1 promotes hematopoietic regeneration via direct and niche-mediated mechanisms Heather A Himburg1,7, Phuong L Doan2,7, Mamle Quarmyne1,3, Xiao Yan1,3, Joshua Sasine1, Liman Zhao1, Grace V Hancock4, Jenny Kan1, Katherine A Pohl1, Evelyn Tran1, Nelson J Chao2, Jeffrey R Harris2 & John P Chute1,5,6 The role of osteolineage cells in regulating hematopoietic stem cell (HSC) regeneration following myelosuppression is not well understood. Here we show that deletion of the pro-apoptotic genes Bak and Bax in osterix (Osx, also known as Sp7 transcription factor 7)-expressing cells in mice promotes HSC regeneration and hematopoietic radioprotection following total body irradiation. These mice showed increased bone marrow (BM) levels of the protein dickkopf-1 (Dkk1), which was produced in Osx-expressing BM cells. Treatment of irradiated HSCs with Dkk1 in vitro increased the recovery of both long-term repopulating HSCs and progenitor cells, and systemic administration of Dkk1 to irradiated mice increased hematopoietic recovery and improved survival. Conversely, inducible deletion of one allele of Dkk1 in Osx-expressing cells in adult mice inhibited the recovery of BM stem and progenitor cells and of complete blood counts following irradiation. Dkk1 promoted hematopoietic regeneration via both direct effects on HSCs, in which treatment with Dkk1 decreased the levels of mitochondrial reactive oxygen species and suppressed senescence, and indirect effects on BM endothelial cells, in which treatment with Dkk1 induced epidermal growth factor (EGF) secretion. Accordingly, blockade of the EGF receptor partially abrogated Dkk1-mediated hematopoietic recovery. These data identify Dkk1 as a regulator of hematopoietic regeneration and demonstrate paracrine cross-talk between BM osteolineage cells and endothelial cells in regulating hematopoietic reconstitution following injury.
  • Supporting Online Material

    Supporting Online Material

    1 2 3 4 5 6 7 Supplementary Information for 8 9 Fractalkine-induced microglial vasoregulation occurs within the retina and is altered early in diabetic 10 retinopathy 11 12 *Samuel A. Mills, *Andrew I. Jobling, *Michael A. Dixon, Bang V. Bui, Kirstan A. Vessey, Joanna A. Phipps, 13 Ursula Greferath, Gene Venables, Vickie H.Y. Wong, Connie H.Y. Wong, Zheng He, Flora Hui, James C. 14 Young, Josh Tonc, Elena Ivanova, Botir T. Sagdullaev, Erica L. Fletcher 15 * Joint first authors 16 17 Corresponding author: 18 Prof. Erica L. Fletcher. Department of Anatomy & Neuroscience. The University of Melbourne, Grattan St, 19 Parkville 3010, Victoria, Australia. 20 Email: [email protected] ; Tel: +61-3-8344-3218; Fax: +61-3-9347-5219 21 22 This PDF file includes: 23 24 Supplementary text 25 Figures S1 to S10 26 Tables S1 to S7 27 Legends for Movies S1 to S2 28 SI References 29 30 Other supplementary materials for this manuscript include the following: 31 32 Movies S1 to S2 33 34 35 36 1 1 Supplementary Information Text 2 Materials and Methods 3 Microglial process movement on retinal vessels 4 Dark agouti rats were anaesthetized, injected intraperitoneally with rhodamine B (Sigma-Aldrich) to label blood 5 vessels and retinal explants established as described in the main text. Retinal microglia were labelled with Iba-1 6 and imaging performed on an inverted confocal microscope (Leica SP5). Baseline images were taken for 10 7 minutes, followed by the addition of PBS (10 minutes) and then either fractalkine or fractalkine + candesartan 8 (10 minutes) using concentrations outlined in the main text.
  • Clinical and Prognostic Significance of MYH11 in Lung Cancer

    Clinical and Prognostic Significance of MYH11 in Lung Cancer

    ONCOLOGY LETTERS 19: 3899-3906, 2020 Clinical and prognostic significance ofMYH11 in lung cancer MENG-JUN NIE1,2, XIAO-TING PAN1,2, HE-YUN TAO1,2, MENG-JUN XU1,2, SHEN-LIN LIU1, WEI SUN1, JIAN WU1 and XI ZOU1 1Oncology Department, The Affiliated Hospital of Nanjing University of Chinese Medicine, Jiangsu Province Hospital of Chinese Medicine, Nanjing, Jiangsu 210029; 2No.1 Clinical Medical College, Nanjing University of Chinese Medicine, Nanjing, Jiangsu 210023, P.R. China Received May 14, 2019; Accepted February 21, 2020 DOI: 10.3892/ol.2020.11478 Abstract. Myosin heavy chain 11 (MYH11), encoded by 5-year survival rate is estimated to approximately 18% (2). the MYH11 gene, is a protein that participates in muscle Therefore, novel targets for drug treatment and prognosis of contraction through the hydrolysis of adenosine triphosphate. lung cancer are needed. Although previous studies have demonstrated that MYH11 Myosin heavy chain 11 (MYH11), which is encoded by gene expression levels are downregulated in several types of the MYH11 gene, is a smooth muscle myosin belonging to the cancer, its expression levels have rarely been investigated in myosin heavy chain family (3). MYH11 is a contractile protein lung cancer. The present study aimed to explore the clinical that slides past actin filaments to induce muscle contraction significance and prognostic value of MYH11 expression levels via adenosine triphosphate hydrolysis (4,5). Previous findings in lung cancer and to further study the underlying molecular have shown that in aortic tissue, destruction of MYH11 can mechanisms of the function of this gene. The Oncomine lead to vascular smooth muscle cell loss, disorganization database showed that the MYH11 expression levels were and hyperplasia, which is one of the mechanisms leading to decreased in lung cancer compared with those noted in the thoracic aortic aneurysms and dissections (6,7).
  • A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus

    A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus

    Page 1 of 781 Diabetes A Computational Approach for Defining a Signature of β-Cell Golgi Stress in Diabetes Mellitus Robert N. Bone1,6,7, Olufunmilola Oyebamiji2, Sayali Talware2, Sharmila Selvaraj2, Preethi Krishnan3,6, Farooq Syed1,6,7, Huanmei Wu2, Carmella Evans-Molina 1,3,4,5,6,7,8* Departments of 1Pediatrics, 3Medicine, 4Anatomy, Cell Biology & Physiology, 5Biochemistry & Molecular Biology, the 6Center for Diabetes & Metabolic Diseases, and the 7Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN 46202; 2Department of BioHealth Informatics, Indiana University-Purdue University Indianapolis, Indianapolis, IN, 46202; 8Roudebush VA Medical Center, Indianapolis, IN 46202. *Corresponding Author(s): Carmella Evans-Molina, MD, PhD ([email protected]) Indiana University School of Medicine, 635 Barnhill Drive, MS 2031A, Indianapolis, IN 46202, Telephone: (317) 274-4145, Fax (317) 274-4107 Running Title: Golgi Stress Response in Diabetes Word Count: 4358 Number of Figures: 6 Keywords: Golgi apparatus stress, Islets, β cell, Type 1 diabetes, Type 2 diabetes 1 Diabetes Publish Ahead of Print, published online August 20, 2020 Diabetes Page 2 of 781 ABSTRACT The Golgi apparatus (GA) is an important site of insulin processing and granule maturation, but whether GA organelle dysfunction and GA stress are present in the diabetic β-cell has not been tested. We utilized an informatics-based approach to develop a transcriptional signature of β-cell GA stress using existing RNA sequencing and microarray datasets generated using human islets from donors with diabetes and islets where type 1(T1D) and type 2 diabetes (T2D) had been modeled ex vivo. To narrow our results to GA-specific genes, we applied a filter set of 1,030 genes accepted as GA associated.
  • Communication Pathways in Human Nonmuscle Myosin-2C 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 Authors: 25 Krishna Chinthalapudia,B,C,1, Sarah M

    Communication Pathways in Human Nonmuscle Myosin-2C 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 Authors: 25 Krishna Chinthalapudia,B,C,1, Sarah M

    1 Mechanistic Insights into the Active Site and Allosteric 2 Communication Pathways in Human Nonmuscle Myosin-2C 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 Authors: 25 Krishna Chinthalapudia,b,c,1, Sarah M. Heisslera,d,1, Matthias Prellera,e, James R. Sellersd,2, and 26 Dietmar J. Mansteina,b,2 27 28 Author Affiliations 29 aInstitute for Biophysical Chemistry, OE4350 Hannover Medical School, 30625 Hannover, 30 Germany. 31 bDivision for Structural Biochemistry, OE8830, Hannover Medical School, 30625 Hannover, 32 Germany. 33 cCell Adhesion Laboratory, Department of Integrative Structural and Computational Biology, The 34 Scripps Research Institute, Jupiter, Florida 33458, USA. 35 dLaboratory of Molecular Physiology, NHLBI, National Institutes of Health, Bethesda, Maryland 36 20892, USA. 37 eCentre for Structural Systems Biology (CSSB), German Electron Synchrotron (DESY), 22607 38 Hamburg, Germany. 39 1K.C. and S.M.H. contributed equally to this work 40 2To whom correspondence may be addressed: E-mail: [email protected] or 41 [email protected] 42 43 1 44 Abstract 45 Despite a generic, highly conserved motor domain, ATP turnover kinetics and their activation by 46 F-actin vary greatly between myosin-2 isoforms. Here, we present a 2.25 Å crystal pre- 47 powerstroke state (ADPVO4) structure of the human nonmuscle myosin-2C motor domain, one 48 of the slowest myosins characterized. In combination with integrated mutagenesis, ensemble- 49 solution kinetics, and molecular dynamics simulation approaches, the structure reveals an 50 allosteric communication pathway that connects the distal end of the motor domain with the 51 active site.
  • Expression of Smooth Muscle and Extracellular Matrix Proteins in Relation to Airway Function in Asthma

    Expression of Smooth Muscle and Extracellular Matrix Proteins in Relation to Airway Function in Asthma

    Expression of smooth muscle and extracellular matrix proteins in relation to airway function in asthma Annelies M. Slats, MD,a Kirsten Janssen, BHe,a Annemarie van Schadewijk, MSc,a Dirk T. van der Plas, BSc,a Robert Schot, BSc,a Joost G. van den Aardweg, MD, PhD,b Johan C. de Jongste, MD, PhD,c Pieter S. Hiemstra, PhD,a Thais Mauad, MD,d Klaus F. Rabe, MD, PhD,a and Peter J. Sterk, MD, PhDa,e Leiden, Alkmaar, Rotterdam, and Amsterdam, The Netherlands, and Sa˜o Paulo, Brazil Background: Smooth muscle content is increased within the selective expression of airway smooth muscle proteins and airway wall in patients with asthma and is likely to play a role in components of the extracellular matrix. (J Allergy Clin airway hyperresponsiveness. However, smooth muscle cells Immunol 2008;121:1196-202.) express several contractile and structural proteins, and each of these proteins may influence airway function distinctly. Key words: Actin, desmin, elastin, airway smooth muscle, extracel- Objective: We examined the expression of contractile and lular matrix, lung function, hyperresponsiveness, deep inspiration- structural proteins of smooth muscle cells, as well as induced bronchodilation, bronchial biopsies extracellular matrix proteins, in bronchial biopsies of patients with asthma, and related these to lung function, airway hyperresponsiveness, and responses to deep inspiration. Asthma is characterized by chronic airway inflammation, Methods: Thirteen patients with asthma (mild persistent, which is presumed to contribute to variable airways obstruction 1 atopic, nonsmoking) participated in this cross-sectional study. and bronchial hyperresponsiveness. However, recent studies FEV1% predicted, PC20 methacholine, and resistance of the have led to a reappraisal of the role of airway smooth muscle in 2 respiratory system by the forced oscillation technique during asthma pathophysiology.
  • Differential Regulation of Proteoglycan 4 Metabolism in Cartilage by IL-1A, IGF-I, and TGF-B1 T

    Differential Regulation of Proteoglycan 4 Metabolism in Cartilage by IL-1A, IGF-I, and TGF-B1 T

    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector Osteoarthritis and Cartilage (2008) 16, 90e97 ª 2007 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved. doi:10.1016/j.joca.2007.05.009 International Cartilage Repair Society Differential regulation of proteoglycan 4 metabolism in cartilage by IL-1a, IGF-I, and TGF-b1 T. A. Schmidt Ph.D., N. S. Gastelum B.S., E. H. Han M.S., G. E. Nugent-Derfus Ph.D., B. L. Schumacher B.S. and R. L. Sah M.D., Sc.D.* Department of Bioengineering and Whitaker Institute of Biomedical Engineering, University of California-San Diego, La Jolla, CA 92093-0412, United States Summary Objectives: To determine (1) if interleukin-1 alpha (IL-1a), insulin like growth factor I (IGF-I), and transforming growth factor-beta 1 (TGF-b1) regulate proteoglycan 4 (PRG4) metabolism in articular cartilage, in terms of chondrocytes expressing PRG4 and PRG4 bound at the articular surface, and (2) if these features of cartilage PRG4 metabolism correlate with its secretion. Methods: Articular cartilage explants were harvested and cultured for 6 days with or without 10% fetal bovine serum (FBS), alone, or with the addition of 10 ng/ml IL-1a, 300 ng/ml IGF-I, or 10 ng/ml TGF-b1. PRG4 expression by chondrocytes in the cartilage disks was assessed by immunohistochemistry (IHC). PRG4 bound to the articular surface of disks was quantified by extraction and enzyme-linked immunosorbent assay (ELISA). PRG4 secreted into culture medium was quantified by ELISA and characterized by Western Blot.
  • PRG4) in Modulating Osteoarthritic Synoviocyte Proliferation and Expression of Matrix Degrading Enzymes Ali Alquraini MCPHS University

    PRG4) in Modulating Osteoarthritic Synoviocyte Proliferation and Expression of Matrix Degrading Enzymes Ali Alquraini MCPHS University

    Chapman University Chapman University Digital Commons Pharmacy Faculty Articles and Research School of Pharmacy 2017 The Autocrine Role of Proteoglycan-4 (PRG4) in Modulating Osteoarthritic Synoviocyte Proliferation and Expression of Matrix Degrading Enzymes Ali Alquraini MCPHS University Maha Jamal MCPHS University Ling Zhang Rhode Island Hospital Tannin Schmidt University of Calgary Gregory D. Jay Rhode Island Hospital FSeoe nelloxtw pa thige fors aaddndition addal aitutionhorsal works at: http://digitalcommons.chapman.edu/pharmacy_articles Part of the Amino Acids, Peptides, and Proteins Commons, Genetic Phenomena Commons, Other Chemicals and Drugs Commons, and the Pharmaceutical Preparations Commons Recommended Citation Alquraini A, Jamal M, Zhang L, Schmidt T, Jay GD, Elsaid KA. The uta ocrine role of proteoglycan-4 (PRG4) in modulating osteoarthritic synoviocyte proliferation and expression of matrix degrading enzymes. Arthritis Research & Therapy. 2017;19:89. doi:10.1186/s13075-017-1301-5. This Article is brought to you for free and open access by the School of Pharmacy at Chapman University Digital Commons. It has been accepted for inclusion in Pharmacy Faculty Articles and Research by an authorized administrator of Chapman University Digital Commons. For more information, please contact [email protected]. The Autocrine Role of Proteoglycan-4 (PRG4) in Modulating Osteoarthritic Synoviocyte Proliferation and Expression of Matrix Degrading Enzymes Comments This article was originally published in Arthritis Research & Therapy, volume 19, in 2017. DOI: 10.1186/ s13075-017-1301-5 Creative Commons License This work is licensed under a Creative Commons Attribution 4.0 License. Copyright The uthora s Authors Ali Alquraini, Maha Jamal, Ling Zhang, Tannin Schmidt, Gregory D. Jay, and Khaled A.
  • Supplementary File 2A Revised

    Supplementary File 2A Revised

    Supplementary file 2A. Differentially expressed genes in aldosteronomas compared to all other samples, ranked according to statistical significance. Missing values were not allowed in aldosteronomas, but to a maximum of five in the other samples. Acc UGCluster Name Symbol log Fold Change P - Value Adj. P-Value B R99527 Hs.8162 Hypothetical protein MGC39372 MGC39372 2,17 6,3E-09 5,1E-05 10,2 AA398335 Hs.10414 Kelch domain containing 8A KLHDC8A 2,26 1,2E-08 5,1E-05 9,56 AA441933 Hs.519075 Leiomodin 1 (smooth muscle) LMOD1 2,33 1,3E-08 5,1E-05 9,54 AA630120 Hs.78781 Vascular endothelial growth factor B VEGFB 1,24 1,1E-07 2,9E-04 7,59 R07846 Data not found 3,71 1,2E-07 2,9E-04 7,49 W92795 Hs.434386 Hypothetical protein LOC201229 LOC201229 1,55 2,0E-07 4,0E-04 7,03 AA454564 Hs.323396 Family with sequence similarity 54, member B FAM54B 1,25 3,0E-07 5,2E-04 6,65 AA775249 Hs.513633 G protein-coupled receptor 56 GPR56 -1,63 4,3E-07 6,4E-04 6,33 AA012822 Hs.713814 Oxysterol bining protein OSBP 1,35 5,3E-07 7,1E-04 6,14 R45592 Hs.655271 Regulating synaptic membrane exocytosis 2 RIMS2 2,51 5,9E-07 7,1E-04 6,04 AA282936 Hs.240 M-phase phosphoprotein 1 MPHOSPH -1,40 8,1E-07 8,9E-04 5,74 N34945 Hs.234898 Acetyl-Coenzyme A carboxylase beta ACACB 0,87 9,7E-07 9,8E-04 5,58 R07322 Hs.464137 Acyl-Coenzyme A oxidase 1, palmitoyl ACOX1 0,82 1,3E-06 1,2E-03 5,35 R77144 Hs.488835 Transmembrane protein 120A TMEM120A 1,55 1,7E-06 1,4E-03 5,07 H68542 Hs.420009 Transcribed locus 1,07 1,7E-06 1,4E-03 5,06 AA410184 Hs.696454 PBX/knotted 1 homeobox 2 PKNOX2 1,78 2,0E-06